PD-L2 is a second ligand for PD-1 and inhibits T cell activation
about
sameAs
The B7 family of immune-regulatory ligandsInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activationThe PD-1 pathway in tolerance and autoimmunityConstitutive and inducible expression of b7 family of ligands by human airway epithelial cellsActive systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) miceMolecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaMolecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interactionThe immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placentaPD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cellsB7x: a widely expressed B7 family member that inhibits T cell activationProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerThe quantal theory of how the immune system discriminates between "self and non-self"Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia.Radiotherapy combination opportunities leveraging immunity for the next oncology practiceMelanoma immunotherapy dominates the fieldA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsClinical significance of T cell metabolic reprogramming in cancerImmune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Checkpoint Inhibitors and Their Application in Breast CancerProgrammed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control StudiesImmunotherapy for lung cancerMedical treatment for gastro-entero-pancreatic neuroendocrine tumoursCancer immunotherapy: the beginning of the end of cancer?Generation of Tolerogenic Dendritic Cells and Their Therapeutic ApplicationsRegulation of Th2 Cell Immunity by Dendritic CellsImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumResults of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancerProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleNovel technologies and emerging biomarkers for personalized cancer immunotherapyB cells with regulatory properties in transplantation toleranceViro-immune therapy: A new strategy for treatment of pancreatic cancerTargeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaPredictive factors for immunotherapy in melanomaHuman Cancer Immunotherapy with PD-1/PD-L1 BlockadeThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsPredictive biomarkers in precision medicine and drug development against lung cancerRole of the PD-1 pathway in the immune response
P2860
Q21184159-59D95FDA-EFAF-4DA9-95F0-AEF051E58E09Q24535835-ED4B008E-25F9-4BD9-83D9-2DEDC1A5FC6AQ24613354-BD12C32A-58D6-423A-80AC-9D17CC2C0ECEQ24633549-920C1E07-6085-4026-850C-3DF09F287056Q24645109-4F4F1D0A-8419-4E4C-829D-9662180B7DB6Q24655393-941533B0-6B5C-4FE7-B71A-833E9B025BC9Q24670319-F3479091-403D-4F9F-9EAB-BED7809FD25BQ24672476-5B68E317-9377-4E77-963F-D0B2F7114E77Q24673269-DE7282AB-46DF-4639-94A1-BC3CC77F2DBFQ24675388-744E711F-3BC7-4FCA-8E40-015EA49663E1Q24677367-EB51976E-6F19-42B8-B52F-875D0A60BB93Q24683252-8E767C77-0E1D-4C3C-8F30-479825B9D94BQ24685406-6141ECDD-7BD1-44B1-B66A-B4771D7667AAQ24803143-0CF22A78-9307-45CF-9D7D-443E3C1A114DQ24805693-F270229C-6378-4EB4-A5AF-AA0F77534F59Q26738443-744A14AB-583A-44A1-B03E-A2FD817BF2F4Q26738671-7AD21A87-0438-4861-A3D6-223A5645593AQ26738729-4232419E-39B0-4D73-A8E8-5D983D693A81Q26741974-3D158CC9-E4A6-4262-AD0B-7B7733B434E8Q26742047-1C57AF47-CF15-4EE3-B260-1CB41BFBC583Q26745442-536CA135-46FE-494B-93BD-55E86ADDEA00Q26749244-927CAED4-961D-4EA5-A9B3-416D5263A057Q26751254-B5C7230C-E819-4783-87DA-3440C7368F82Q26751659-0A4D23EF-08ED-4642-B9E8-991F2B63F621Q26752277-A88E8918-BBEA-44F6-A0ED-E5FE5A09FC5EQ26764855-955F0B9D-5390-4EC9-971D-7D4BB7D96DF1Q26764869-1F77774D-20DB-436D-B704-D472E9095A6EQ26765459-1BC8D47F-37E9-401F-8157-4E603FE7A11EQ26769713-06337E66-A5AE-4810-80A3-9ADD14DCB523Q26769734-FDFD9672-766D-4ADE-B124-C35BB51F9B42Q26770780-CDE6043C-1D51-494B-848C-D75F8EFA5B8BQ26771404-2CA6A106-0F07-4737-B268-B7029B1358D0Q26774641-4E87BADD-9B2B-49CF-9FDA-4A761B49C3A9Q26775769-FDD5C628-87DE-4158-8516-7E44FF969685Q26778765-118D58D4-3A2A-47F8-8781-41A2928C9752Q26786108-E866B84F-9BFE-4B1C-94F9-E809074922DBQ26797478-15B83B07-AED0-49D8-8ADC-4DFC802C711AQ26823789-67E6B176-C794-4FD8-89D4-84C8A9207528Q26824536-6F132925-42AE-47F8-B40A-D6AEC42F4D85Q26828748-9B22A717-0214-4CE5-9B8D-0F70B2E96F6D
P2860
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@ast
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@en
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@nl
type
label
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@ast
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@en
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@nl
prefLabel
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@ast
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@en
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@nl
P2093
P3181
P356
P1433
P1476
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
@en
P2093
A H Sharpe
B M Carreno
D Chaudhary
E A Greenfield
G J Freeman
H Nishimura
I Chernova
P3181
P356
10.1038/85330
P407
P577
2001-03-01T00:00:00Z